SCOPUS 정보 검색 플랫폼

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 5, 2014, Pages 274-276

NASH: The tribulations of conducting NASH trials

(1) Neuschwander Tetri, Brent A a

a SAINT LOUIS UNIVERSITY (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE IV INHIBITOR; TUMOR NECROSIS FACTOR;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MODEL; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; EXPERIMENTAL ANIMAL; HUMAN; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STUDY DESIGN; FEMALE; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

FEMALE; HUMANS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; PHOSPHODIESTERASE 4 INHIBITORS;

EID: 84900394543 PISSN: 17595045 EISSN: 17595053 Source Type: Journal
DOI: 10.1038/nrgastro.2014.51 Document Type: Article

Times cited : (2)

References (10)

1
- 84874645372
- Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010
- e491
- Welsh, J. A., Karpen, S. & Vos, M. B. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J. Pediatr. 162, 496-500. e491 (2013).
- (2013) J. Pediatr. , vol.162 , pp. 496-500
- Welsh, J.A.¹ Karpen, S.² Vos, M.B.³

2
- 84887320114
- The global NAFLD epidemic
- Loomba, R. & Sanyal, A. J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 686-690 (2013).
- (2013) Nat. Rev. Gastroenterol. Hepatol. , vol.10 , pp. 686-690
- Loomba, R.¹ Sanyal, A.J.²

3
- 79959573040
- Endpoints and clinical trial design for nonalcoholic steatohepatitis
- Sanyal, A. J. et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54, 344-353 (2011).
- (2011) Hepatology , vol.54 , pp. 344-353
- Sanyal, A.J.¹

4
- 84908090042
- Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis
- Ratziu, V. et al. Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. http://dx. doi. org/10. 1016/j. cgh. 2014. 01. 040.
- Clin. Gastroenterol. Hepatol.
- Ratziu, V.¹

5
- 52949140176
- PDE4 inhibitors: Current status
- Spina, D. PDE4 inhibitors: current status. Br. J. Pharmacol. 155, 308-315 (2008).
- (2008) Br. J. Pharmacol. , vol.155 , pp. 308-315
- Spina, D.¹

6
- 84868632227
- Why is publication of negative clinical trial data important?
- Hayes, A. & Hunter, J. Why is publication of negative clinical trial data important? Br. J. Pharmacol. 167, 1395-1397, (2012).
- (2012) Br. J. Pharmacol. , vol.167 , pp. 1395-1397
- Hayes, A.¹ Hunter, J.²

7
- 78651089694
- Animal models of nonalcoholic fatty liver disease
- Hebbard, L. & George, J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 8, 35-44 (2011).
- (2011) Nat. Rev. Gastroenterol. Hepatol. , vol.8 , pp. 35-44
- Hebbard, L.¹ George, J.²

8
- 79959520068
- New insights from rodent models of fatty liver disease
- Maher, J. J. New insights from rodent models of fatty liver disease. Antioxid. Redox. Signal. 15, 535-550 (2011).
- (2011) Antioxid. Redox. Signal. , vol.15 , pp. 535-550
- Maher, J.J.¹

9
- 79954484784
- Animal models for the study of hepatic fibrosis. Baillieres best pract
- Stärkel, P. & Leclercq, I. A. Animal models for the study of hepatic fibrosis. Baillieres Best Pract. Res. Clin. Gastroenterol. 25, 319-333 (2011).
- (2011) Res. Clin. Gastroenterol. , vol.25 , pp. 319-333
- Stärkel, P.¹ Leclercq, I.A.²

10
- 84887321419
- NAFLD, NASH and liver cancer
- Michelotti, G. A., Machado, M. V. & Diehl, A. M. NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 10, 656-665 (2013).
- (2013) Nat. Rev. Gastroenterol. Hepatol. , vol.10 , pp. 656-665
- Michelotti, G.A.¹ Machado, M.V.² Diehl, A.M.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.